To access the full text documents, please follow this link: http://hdl.handle.net/2117/22665
dc.contributor | Universitat Politècnica de Catalunya. Departament d'Organització d'Empreses |
---|---|
dc.contributor | Universitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa |
dc.contributor | Universitat Politècnica de Catalunya. GREMA - Grup de Recerca en Estadística Matemàtica i les seves Aplicacions |
dc.contributor.author | Echeverria, Patricia |
dc.contributor.author | Bonjoch, Anna |
dc.contributor.author | Puig Batalla, Jorge |
dc.contributor.author | Molto, Jose |
dc.contributor.author | Paredes, Roger |
dc.contributor.author | Sirera, Guillem |
dc.contributor.author | Ornelas, Arelly |
dc.contributor.author | Pérez Álvarez, Nuria |
dc.contributor.author | Clotet, Bonaventura |
dc.contributor.author | Negredo, Eugènia |
dc.date | 2014-02-04 |
dc.identifier.citation | Echeverria, P. [et al.]. Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study. "PLoS One", 04 Febrer 2014, vol. 9, núm. 2. |
dc.identifier.citation | 1932-6203 |
dc.identifier.citation | 10.1371/journal.pone.0084676 |
dc.identifier.citation | 24503952 |
dc.identifier.uri | http://hdl.handle.net/2117/22665 |
dc.language.iso | eng |
dc.rights | Attribution 3.0 Spain |
dc.rights | info:eu-repo/semantics/openAccess |
dc.rights | http://creativecommons.org/licenses/by/3.0/es/ |
dc.subject | Àrees temàtiques de la UPC::Ciències de la salut |
dc.subject | Virus-induced immunosuppression |
dc.subject | HIV (Viruses)--Research |
dc.subject | Reverse-transcriptase inhibitor |
dc.subject | Placebo-controlled trial |
dc.subject | Experienced HIV-1-infected patients |
dc.subject | Immunodeficiency-virus-infection |
dc.subject | Treatment-naive patients |
dc.subject | Double-blind |
dc.subject | TMC125 etravirine |
dc.subject | Antiretroviral treatment |
dc.subject | HDL-cholesterol |
dc.subject | Lipid profiles |
dc.subject | VIH (Virus) -- Tractament |
dc.title | Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study |
dc.type | info:eu-repo/semantics/publishedVersion |
dc.type | info:eu-repo/semantics/article |
dc.description.abstract | |
dc.description.abstract |